ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BCR/ABL have been also described. In the present rep...

Full description

Bibliographic Details
Main Authors: Clara I Aceves-Luquero, Anupriya Agarwal, Juan L Callejas-Valera, Laura Arias-González, Azucena Esparís-Ogando, Luis del Peso Ovalle, Itxaso Bellón-Echeverria, Miguel A de la Cruz-Morcillo, Eva M Galán Moya, Inmaculada Moreno Gimeno, Juan C Gómez, Michael W Deininger, Atanasio Pandiella, Ricardo Sánchez Prieto
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-07-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19568437/pdf/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19568437/pdf/?tool=EBI

Similar Items